aluminum sulfate has been researched along with Leishmaniasis, American in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arthun, EN; Dow, SW; Regan, DP; Spencer, JS; Titus, RG; Wheat, WH | 1 |
| Keshavarz, H; Khamesipour, A; Nateghi Rostami, M | 1 |
| Belkaid, Y; Bertholet, S; Klinman, D; Mendez, S; Sacks, DL; Seder, RA; Tabbara, K; Verthelyi, D | 1 |
| Chan, AS; Hochberg, L; Martin, SK; Mbow, ML; Mejia, JS; Ryan, JR; Titus, RG; Tonui, WK | 1 |
| Akuffo, H; Eidsmo, L; Jafari-Shakib, R; Khamesipour, A; Modabber, F; Mohammadi, A; Noazin, S; Nylén, S | 1 |
| Evans-Davis, K; Gam, AA; Kenney, RT; Sacks, DL; Sypek, JP; Vilela, L | 1 |
1 trial(s) available for aluminum sulfate and Leishmaniasis, American
| Article | Year |
|---|---|
Surrogate markers of immunity to Leishmania major in leishmanin skin test negative individuals from an endemic area re-visited.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Alum Compounds; Animals; Antigens, Protozoan; Biomarkers; Cytokines; Double-Blind Method; Endemic Diseases; Enzyme-Linked Immunosorbent Assay; Female; Humans; Interferon-gamma; Leishmania major; Leishmaniasis, Cutaneous; Male; Mycobacterium bovis; Phenotype; Skin Tests | 2006 |
5 other study(ies) available for aluminum sulfate and Leishmaniasis, American
| Article | Year |
|---|---|
Immunization against full-length protein and peptides from the Lutzomyia longipalpis sand fly salivary component maxadilan protects against Leishmania major infection in a murine model.
Topics: Adjuvants, Immunologic; Alum Compounds; Animals; Cations; CD4-Positive T-Lymphocytes; Disease Models, Animal; DNA; Immunization; Insect Proteins; Leishmania major; Leishmaniasis, Cutaneous; Liposomes; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Peptides; Psychodidae; Saliva | 2017 |
Immune response of BALB/c mice against an experimental vaccine of Alum precipitated autoclaved Leishmania major (Alum-ALM) mixed with BCG or Mycobacterium vaccae.
Topics: Alum Compounds; Animals; Antibodies, Protozoan; Chemical Precipitation; Hypersensitivity, Delayed; Leishmaniasis Vaccines; Leishmaniasis, Cutaneous; Mice; Mice, Inbred BALB C; Mycobacterium; Mycobacterium bovis; Vaccines, Inactivated | 2010 |
Coinjection with CpG-containing immunostimulatory oligodeoxynucleotides reduces the pathogenicity of a live vaccine against cutaneous Leishmaniasis but maintains its potency and durability.
Topics: Adjuvants, Immunologic; Alum Compounds; Animals; CD4-Positive T-Lymphocytes; Humans; Interferon-gamma; Interleukin-10; Leishmania major; Leishmaniasis, Cutaneous; Mice; Mice, Inbred C57BL; Oligodeoxyribonucleotides; Protozoan Vaccines; Safety; Skin; Time Factors | 2003 |
Immunization with Leishmania major exogenous antigens protects susceptible BALB/c mice against challenge infection with L. major.
Topics: Adjuvants, Immunologic; Alum Compounds; Animals; Antigens, Protozoan; Female; Glycosphingolipids; Interleukin-12; Leishmania major; Leishmaniasis, Cutaneous; Membrane Glycoproteins; Mice; Mice, Inbred BALB C; Protozoan Proteins; Protozoan Vaccines; Th1 Cells; Th2 Cells; Vaccination | 2004 |
Protective immunity using recombinant human IL-12 and alum as adjuvants in a primate model of cutaneous leishmaniasis.
Topics: Adjuvants, Immunologic; Alum Compounds; Animals; Disease Models, Animal; Dose-Response Relationship, Immunologic; Humans; Immunity, Active; Interferon-gamma; Interleukin-12; Leishmaniasis, Cutaneous; Macaca mulatta; Protozoan Vaccines; Vaccines, Synthetic | 1999 |